Home › Obesity › NCT03866408

Insulin Regulation of Lipolysis and Lipolysis Proteins

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Men and Women between the ages of 18 and 55.
* Women will be premenopausal
* Non obese adults BMI between 18-25
* Obese BMI 30-38

Exclusion Criteria, Pioglitazone package insert of contraindications for use:

* Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
* Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.

About the study

These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.

What is being tested

• Immediate weight loss (behavioral)
• Pioglitazone (drug)
• Deferred weight loss (behavioral)
• Placebo (drug)

Sponsor: Mayo Clinic · Participants: 64 · Started: Nov 12, 2018

Contact the study team

Official record on ClinicalTrials.gov — NCT03866408

Locations in the U.S.

Conditions

• Obesity

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.